Tuesday, January 31, 2023
Sun Pharmaceutical announced that it has acquired three brands viz. Disperzyme® (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care (“Aksigen”). All the brands are approved by the Drugs Controller General of India (“DCGI”) for post-operative inflammation in patients undergoing minor surgery and dental procedures.
Disperzyme® and Phlogam® are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and to get DCGI approval.
Disperzyme® and Phlogam®, administered orally, offers systemic enzyme-flavonoid therapy. Disperzyme® and Phlogam® provides the clinicians an evidence-based management solution for inflammation and pain management after minor surgery and dental procedures.
The addition of Disperzyme® and Phlogam® further strengthens anti-inflammatory portfolio. This systemic enzyme therapy combination controls oedema and it speeds-up the healing process. In a comparative clinical trial in India, these brands provides significantly better control and resolution of post-operative pain and inflammation.
